Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07151521

(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis

Application Value of Novel PET Tracers Targeting CAF in ANCA-Associated Vasculitis

Status
Recruiting
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Ruijin Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Pulmonary and renal involvement are the most common clinical manifestations of antineutrophil cytoplasmic antibody(ANCA)-associated vasculitis (AAV). Studies have shown that both interstitial lung disease (ILD) and renal dysfunction are closely associated with poor prognosis in patients with AAV. Therefore, early identification of whether AAV patients have concomitant ILD and renal involvement is of great clinical importance for assessing disease severity, stratifying prognostic risk, and developing individualized treatment strategies. Positron emission tomography (PET) is a noninvasive molecular imaging technique that can provide decision-making support for early and accurate diagnosis, timely intervention, as well as evaluation of treatment response and prognosis. In the same individual, PET enables whole-body localization of disease in a single examination, overcoming the limitation of conventional diagnostic methods that typically assess only one region at a time, thereby facilitating patient benefit. In recent years, many novel PET tracers have been developed and introduced into clinical practice. 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) has been studied in the diagnosis of various malignant and nonmalignant diseases; it targets fibroblast activation protein (FAP) and thus reflects the distribution of cancer-associated fibroblasts (CAFs). However, its clinical significance in AAV remains to be further investigated. This study aims to use a CAF-targeted novel PET tracer to conveniently and noninvasively detect the real-time distribution of lesions in patients, providing valuable information for personalized diagnosis and treatment.

Conditions

Timeline

Start date
2025-09-01
Primary completion
2027-07-01
Completion
2028-07-01
First posted
2025-09-03
Last updated
2025-11-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07151521. Inclusion in this directory is not an endorsement.